live In the news:
Sage Therapeutics Jumps on Biogen's $469 Million Takeover Offer

Sage Therapeutics

8 days ago
bookmarkBookmark

Sage Therapeutics is a company. It is in Cambridge, the United States and it has a male CEO called Barry E. Greene. It was founded in 2010 and is part of the Health Care sector, specifically in the Biotechnology industry.

Key facts

plus See more facts
link LinkedIn: 54K followers
link X (Twitter): 3K followers


Extract data

Download datasets about Sage Therapeutics:

dataset Dataset of stocks from Sage Therapeutics:

Sage Therapeutics is one of the companies in Biotechnology, companies in Health Care, companies in Cambridge, companies in the United States and 3,456,835 companies in our database.

Talking Points

  • Biopharmaceutical Company for Brain Health Medicine | Sage Therapeutics
  • Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.
  • Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Community Guidelines: https://t.co/O3kvO0DUOA
  • Our mission is to make medicines that matter so people can get better, sooner. | Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and our ...
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
  • Enjoy the Journey
  • Our mission is to make medicines that matter so people can get better, sooner. | Sage Therapeutics is a biopharmaceutical company committed to ...

Related

Connected or similar to Sage Therapeutics: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.